HB-EGF protects the lungs after intestinal ischemia/reperfusion injury

Iyore A O James, Chun-liang Chen, Guangcun Huang, Hong Yi Zhang, Markus Velten, Gail E. Besner

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Acute respiratory distress syndrome continues to be a major source of morbidity and mortality in critically-ill patients. Heparin binding EGF-like growth factor (HB-EGF) is a biologically active protein that acts as an intestinal cytoprotective agent. We have previously demonstrated that HB-EGF protects the intestines from injury in several different animal models of intestinal injury. In the current study, we investigated the ability of HB-EGF to protect the lungs from remote organ injury after intestinal ischemia/reperfusion (I/R). Methods: Mice were randomly assigned to one of the following groups: (1) sham-operated; (2) sham+HB-EGF (1200 μg/kg in 0.6 mL administered by intra-luminal injection at the jejuno-ileal junction immediately after identification of the superior mesenteric artery); (3) superior mesenteric artery occlusion for 45 min followed by reperfusion for 6 h (I/R); or (4) I/R+HB-EGF (1200 μg/kg in 0.6 mL) administered 15 min after vascular occlusion. The severity of acute lung injury was determined by histology, morphometric analysis and invasive pulmonary function testing. Animal survival was evaluated using Kaplan-Meier analysis. Results: Mice subjected to intestinal I/R injury showed histologic and functional evidence of acute lung injury and decreased survival compared with sham-operated animals. Compared with mice treated with HB-EGF (I/R+HB-EGF), the I/R group had more severe acute lung injury, and decreased survival. Conclusion: Our results demonstrate that HB-EGF reduces the severity of acute lung injury after intestinal I/R in mice. These data demonstrate that HB-EGF may be a potential novel systemic anti-inflammatory agent for the prevention of the systemic inflammatory response syndrome (SIRS) after intestinal injury.

Original languageEnglish (US)
Pages (from-to)86-95
Number of pages10
JournalJournal of Surgical Research
Volume163
Issue number1
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Reperfusion Injury
Reperfusion
Lung
Ischemia
Acute Lung Injury
Superior Mesenteric Artery
Wounds and Injuries
Heparin-binding EGF-like Growth Factor
Systemic Inflammatory Response Syndrome
Survival
Adult Respiratory Distress Syndrome
Kaplan-Meier Estimate
Critical Illness
Intestines
Blood Vessels
Histology
Anti-Inflammatory Agents
Animal Models
Morbidity
Injections

Keywords

  • acute lung injury
  • HB-EGF
  • heparin-binding EGF-like growth factor
  • intestine
  • lungs
  • multiple organ dysfunction syndrome
  • systemic inflammatory response

ASJC Scopus subject areas

  • Surgery

Cite this

James, I. A. O., Chen, C., Huang, G., Zhang, H. Y., Velten, M., & Besner, G. E. (2010). HB-EGF protects the lungs after intestinal ischemia/reperfusion injury. Journal of Surgical Research, 163(1), 86-95. https://doi.org/10.1016/j.jss.2010.03.062

HB-EGF protects the lungs after intestinal ischemia/reperfusion injury. / James, Iyore A O; Chen, Chun-liang; Huang, Guangcun; Zhang, Hong Yi; Velten, Markus; Besner, Gail E.

In: Journal of Surgical Research, Vol. 163, No. 1, 09.2010, p. 86-95.

Research output: Contribution to journalArticle

James, IAO, Chen, C, Huang, G, Zhang, HY, Velten, M & Besner, GE 2010, 'HB-EGF protects the lungs after intestinal ischemia/reperfusion injury', Journal of Surgical Research, vol. 163, no. 1, pp. 86-95. https://doi.org/10.1016/j.jss.2010.03.062
James, Iyore A O ; Chen, Chun-liang ; Huang, Guangcun ; Zhang, Hong Yi ; Velten, Markus ; Besner, Gail E. / HB-EGF protects the lungs after intestinal ischemia/reperfusion injury. In: Journal of Surgical Research. 2010 ; Vol. 163, No. 1. pp. 86-95.
@article{1fb2317b946c4bca8977a3e6cde9a86b,
title = "HB-EGF protects the lungs after intestinal ischemia/reperfusion injury",
abstract = "Background: Acute respiratory distress syndrome continues to be a major source of morbidity and mortality in critically-ill patients. Heparin binding EGF-like growth factor (HB-EGF) is a biologically active protein that acts as an intestinal cytoprotective agent. We have previously demonstrated that HB-EGF protects the intestines from injury in several different animal models of intestinal injury. In the current study, we investigated the ability of HB-EGF to protect the lungs from remote organ injury after intestinal ischemia/reperfusion (I/R). Methods: Mice were randomly assigned to one of the following groups: (1) sham-operated; (2) sham+HB-EGF (1200 μg/kg in 0.6 mL administered by intra-luminal injection at the jejuno-ileal junction immediately after identification of the superior mesenteric artery); (3) superior mesenteric artery occlusion for 45 min followed by reperfusion for 6 h (I/R); or (4) I/R+HB-EGF (1200 μg/kg in 0.6 mL) administered 15 min after vascular occlusion. The severity of acute lung injury was determined by histology, morphometric analysis and invasive pulmonary function testing. Animal survival was evaluated using Kaplan-Meier analysis. Results: Mice subjected to intestinal I/R injury showed histologic and functional evidence of acute lung injury and decreased survival compared with sham-operated animals. Compared with mice treated with HB-EGF (I/R+HB-EGF), the I/R group had more severe acute lung injury, and decreased survival. Conclusion: Our results demonstrate that HB-EGF reduces the severity of acute lung injury after intestinal I/R in mice. These data demonstrate that HB-EGF may be a potential novel systemic anti-inflammatory agent for the prevention of the systemic inflammatory response syndrome (SIRS) after intestinal injury.",
keywords = "acute lung injury, HB-EGF, heparin-binding EGF-like growth factor, intestine, lungs, multiple organ dysfunction syndrome, systemic inflammatory response",
author = "James, {Iyore A O} and Chun-liang Chen and Guangcun Huang and Zhang, {Hong Yi} and Markus Velten and Besner, {Gail E.}",
year = "2010",
month = "9",
doi = "10.1016/j.jss.2010.03.062",
language = "English (US)",
volume = "163",
pages = "86--95",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - HB-EGF protects the lungs after intestinal ischemia/reperfusion injury

AU - James, Iyore A O

AU - Chen, Chun-liang

AU - Huang, Guangcun

AU - Zhang, Hong Yi

AU - Velten, Markus

AU - Besner, Gail E.

PY - 2010/9

Y1 - 2010/9

N2 - Background: Acute respiratory distress syndrome continues to be a major source of morbidity and mortality in critically-ill patients. Heparin binding EGF-like growth factor (HB-EGF) is a biologically active protein that acts as an intestinal cytoprotective agent. We have previously demonstrated that HB-EGF protects the intestines from injury in several different animal models of intestinal injury. In the current study, we investigated the ability of HB-EGF to protect the lungs from remote organ injury after intestinal ischemia/reperfusion (I/R). Methods: Mice were randomly assigned to one of the following groups: (1) sham-operated; (2) sham+HB-EGF (1200 μg/kg in 0.6 mL administered by intra-luminal injection at the jejuno-ileal junction immediately after identification of the superior mesenteric artery); (3) superior mesenteric artery occlusion for 45 min followed by reperfusion for 6 h (I/R); or (4) I/R+HB-EGF (1200 μg/kg in 0.6 mL) administered 15 min after vascular occlusion. The severity of acute lung injury was determined by histology, morphometric analysis and invasive pulmonary function testing. Animal survival was evaluated using Kaplan-Meier analysis. Results: Mice subjected to intestinal I/R injury showed histologic and functional evidence of acute lung injury and decreased survival compared with sham-operated animals. Compared with mice treated with HB-EGF (I/R+HB-EGF), the I/R group had more severe acute lung injury, and decreased survival. Conclusion: Our results demonstrate that HB-EGF reduces the severity of acute lung injury after intestinal I/R in mice. These data demonstrate that HB-EGF may be a potential novel systemic anti-inflammatory agent for the prevention of the systemic inflammatory response syndrome (SIRS) after intestinal injury.

AB - Background: Acute respiratory distress syndrome continues to be a major source of morbidity and mortality in critically-ill patients. Heparin binding EGF-like growth factor (HB-EGF) is a biologically active protein that acts as an intestinal cytoprotective agent. We have previously demonstrated that HB-EGF protects the intestines from injury in several different animal models of intestinal injury. In the current study, we investigated the ability of HB-EGF to protect the lungs from remote organ injury after intestinal ischemia/reperfusion (I/R). Methods: Mice were randomly assigned to one of the following groups: (1) sham-operated; (2) sham+HB-EGF (1200 μg/kg in 0.6 mL administered by intra-luminal injection at the jejuno-ileal junction immediately after identification of the superior mesenteric artery); (3) superior mesenteric artery occlusion for 45 min followed by reperfusion for 6 h (I/R); or (4) I/R+HB-EGF (1200 μg/kg in 0.6 mL) administered 15 min after vascular occlusion. The severity of acute lung injury was determined by histology, morphometric analysis and invasive pulmonary function testing. Animal survival was evaluated using Kaplan-Meier analysis. Results: Mice subjected to intestinal I/R injury showed histologic and functional evidence of acute lung injury and decreased survival compared with sham-operated animals. Compared with mice treated with HB-EGF (I/R+HB-EGF), the I/R group had more severe acute lung injury, and decreased survival. Conclusion: Our results demonstrate that HB-EGF reduces the severity of acute lung injury after intestinal I/R in mice. These data demonstrate that HB-EGF may be a potential novel systemic anti-inflammatory agent for the prevention of the systemic inflammatory response syndrome (SIRS) after intestinal injury.

KW - acute lung injury

KW - HB-EGF

KW - heparin-binding EGF-like growth factor

KW - intestine

KW - lungs

KW - multiple organ dysfunction syndrome

KW - systemic inflammatory response

UR - http://www.scopus.com/inward/record.url?scp=77955920288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955920288&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2010.03.062

DO - 10.1016/j.jss.2010.03.062

M3 - Article

C2 - 20599214

AN - SCOPUS:77955920288

VL - 163

SP - 86

EP - 95

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -